Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients at early stage of the disease.

Timeline

Start

2016-10-17

Primary completion

2018-01-29

Completion

2018-01-29

Outcome

Met primary endpoint

Stopped: “Study B7601011 was terminated on 29 Jan 2018 due to lack of efficacy in moderate/advanced Parkinson's disease.”

paper the study met its primary endpoint with the PF-06649751 group showing statistically significant improvement PMID 32201505 ↗

paper This corresponds to an improvement versus placebo of 4.8 for the PF-06649751 group (two-sided p = 0.0407; 90% CI = 1.0, 8.6). PMID 32201505 ↗

release “Phase 2 clinical trial evaluating oral tavapadon (formerly PF-06649751) in patients with early-stage Parkinson’s disease. The study met its primary endpoint” abbvie.com ↗

Publications

• Riesenberg R, Werth J, Zhang Y, Duvvuri S, Gray D. PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial. Ther Adv Neurol Disord. 2020 Mar 6;13:1756286420911296. doi: 10.1177/1756286420911296. eCollection 2020.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tavapadon	Small molecule	—	Oral

Indications